<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319757</url>
  </required_header>
  <id_info>
    <org_study_id>ACE1702-001</org_study_id>
    <nct_id>NCT04319757</nct_id>
  </id_info>
  <brief_title>ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors</brief_title>
  <official_title>A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acepodia Biotech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acepodia Biotech Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that&#xD;
      targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate&#xD;
      the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of&#xD;
      ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the&#xD;
      phase Ib/II starting dose for ACE1702.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, including Dose Limiting Toxicities (DLTs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 7 through Day 28</time_frame>
    <description>Number of subjects experiencing adverse events, and the frequency and severity of adverse events.&#xD;
Endpoint for determining the Maximum Tolerated Dose (MTD). If MTD is not identified, the highest dose administered becomes the Maximum Administered Dose (MAD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib/II starting dose for ACE1702</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>The recommended phase Ib/II starting dose based on MTD. If MTD is not reached, then the recommended phase Ib/II dose will be determined based on the MAD, safety data, and pharmacodynamics data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantify NK cell persistence after administering ACE1702</measure>
    <time_frame>Day 21</time_frame>
    <description>Duration of ACE1702 persistence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate immune function after administering ACE1702</measure>
    <time_frame>Day 21</time_frame>
    <description>Measurement of serum cytokine levels, pg/mL (Interferon-γ, TNF-α, IL-2, IL-6, IL-8 and IL-10) at set timepoints</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor response using Response Evaluation Criteria In Solid Tumors Assessment (RECIST) version 1.1</measure>
    <time_frame>Day 35 (+7 day window) of each 6 week cycle, up to 24 months</time_frame>
    <description>Tumor response via radiographic assessments</description>
  </other_outcome>
  <other_outcome>
    <measure>Shift in serum tumor marker values (CA-125, CA 19-9, and CEA levels, in applicable tumor types)</measure>
    <time_frame>Day 35 (+7 day window) of each 6 week cycle, up to 24 months</time_frame>
    <description>Tumor response via tumor marker assessments (in applicable tumor types)</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Locally Advanced Solid Tumor</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>HER2-positive Gastric Cancer</condition>
  <condition>HER2-positive Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ACE1702 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 immunohistochemistry (IHC) 2+ or above.&#xD;
Dose Level: 1 Planned number of subjects: 1 to 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE1702 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.&#xD;
Dose Level: 2 Planned number of subjects: 1 to 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE1702 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.&#xD;
Dose Level: 3 Planned number of subjects: 3 to 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE1702 Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.&#xD;
Dose Level: 4 Planned number of subjects: 3 to 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE1702 Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.&#xD;
Dose Level: 5 Planned number of subjects: 3 to 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE1702 Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.&#xD;
Dose Level: 6 Planned number of subjects: 3 to 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE1702</intervention_name>
    <description>ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously</description>
    <arm_group_label>ACE1702 Dose 6</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 1</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 2</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 3</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 4</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>ACE1702 Dose 6</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 1</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 2</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 3</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 4</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>ACE1702 Dose 6</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 1</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 2</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 3</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 4</arm_group_label>
    <arm_group_label>ACE1702 Dose Level 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Subjects must be ≥ 18 years of age&#xD;
&#xD;
          -  Subject with advanced or metastatic solid tumors that is not amenable to surgical&#xD;
             resection and is not eligible or has refused other approved therapeutic options that&#xD;
             have demonstrated clinical benefit.&#xD;
&#xD;
          -  Histologically confirmed HER2 expression.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1&#xD;
&#xD;
          -  Measurable or non-measurable evaluable disease according to RECIST 1.1&#xD;
&#xD;
          -  Adequate hematologic and end-organ function at baseline&#xD;
&#xD;
          -  Oxygen saturation via pulse oxygenation ≥ 90% at rest on room air&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated central nervous system (CNS) metastases&#xD;
&#xD;
          -  Multiple primary malignancies&#xD;
&#xD;
          -  Clinically significant cardiovascular disease such as New York Heart Association&#xD;
             (NYHA) cardiac disease (class III or greater)&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Serious, uncontrolled medical disorder that, in the opinion of the Investigator, would&#xD;
             impair the ability of the subject to receive study treatment&#xD;
&#xD;
          -  History of autoimmune or immune mediated symptomatic disease&#xD;
&#xD;
          -  Any anti-cancer chemotherapy or targeted small molecule therapy, or experimental&#xD;
             therapy/device within 4 weeks or 5 half-lives of the drug prior to planned start of&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kurman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acepodia Biotech Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet Pan, MPH</last_name>
    <phone>+1-415-839-6787</phone>
    <email>clinical@acepodiabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern Univeristy</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NK Cell Therapy</keyword>
  <keyword>Cellular Therapy</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Metastatic Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Non-small-cell Lung Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

